Lv6
2248 积分 2024-08-08 加入
图奇吃悠米
Efficacy, Safety, and Biomarker Analysis of Toripalimab Monoclonal Antibody Combined With Gemcitabine and Cisplatin Chemotherapy as Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: A Phase II Clinical Trial
2小时前
已完结
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
11天前
已完结
Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial
16天前
已完结
Adjuvant immunotherapy versus observation in patients with lymph node-positive status after neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a prospective, single-center, controlled phase II study
21天前
已完结
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma
21天前
已完结
A Phase III Multicenter Randomized Clinical Trial of 60 Gy versus 50 Gy Radiation Dose in Concurrent Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma
1个月前
已完结
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
1个月前
已完结
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial
2个月前
已完结
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma
2个月前
已完结
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
2个月前
已完结
皖公网安备34019202002308
